Home » Breast Cancer » Breast Cancer – Risk of Recurrence

Breast Cancer – Risk of Recurrence

Available Tests:
Oncotype DX® Breast Cancer Assay
Available from: Your oncologist in Ireland or Oncotypeiq
The Oncotype DX® Breast Cancer Assay can help physicians and patients decide on the best course of treatment. For invasive breast cancer, the Oncotype DX Breast Cancer Assay predicts chemotherapy benefit and the likelihood of distant breast cancer recurrence. The Oncotype DX Breast Cancer Assay for DCIS patients predicts the risk of local recurrence. Article source: Oncotypeiq

Available from: Agendia.com (through your physician).
Agendia’s MammaPrint is a test which determines how aggressive a breast cancer tumour is. The MammaPrint result will enable your physician to determine what would be the best kind of treatment for you following your operation. Source: agendia.com

Available from: Nanostring Technologies (through your physician).
Prosigna provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer.

The Prosigna Assay will be available for diagnostic use when ordered by a physician in the U.S. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark and in which Prosigna is registered. Source: Nanostring Technologies

Available from: Myriad Genetics Inc.
EndoPredict is a 2nd generation breast cancer recurrence test for highly accurate assessment of 10-year risk of distant recurrence. Both gene expression with clinicopathological features are integrated into the EndoPredict test result to provide improved prognostic performance.
EndoPredict is appropriate for women with:

Updated 2023

Cancer Tests

Please share this page to help others